peptide sciences tirzepatide reviews Is a Stimulant? Mechanism and Safety Profile Tirzepatide 10mg — GLP-1/GIP Dual-Agonist

Safety Profile: What We Learned About Side Effects Common Adverse Events The TRIUMPH-4 trial confirmed that retatrutide's side effect profile aligns with other incretin-based therapies, with gastrointestinal symptoms being the most common: Incidence of GI Side Effects (12mg dose): Nausea: 43% (vs 11% placebo) Diarrhea: 33% (vs 13% placebo) Vomiting: 21% (vs 0% placebo) Constipation: Elevated vs placebo Decreased appetite: Common Most gastrointestinal side effects were mild to moderate in severity and occurred primarily during the dose escalation phase

A fascinating story that opens a new chapter in GSH field Congrats Isaac and the rest of the Harris Lab

FASEB J (2014) 28:41629.10.1096/fj.13-229591 87 NovakNAllamJP

Reassess regularly

Once a month inter-rater reliability will be analysed for quality control